Clonal Hematopoiesis and Thrombotic Risk Beyond Cancer: A Comprehensive Review for Clinicians

Abstract

Clonal hematopoiesis (CH), particularly clonal hematopoiesis of indeterminate potential (CHIP), has emerged as a significant risk factor for thrombotic events, extending far beyond its established associations with hematologic malignancies. Recent studies have elucidated the pathophysiological mechanisms by which somatic mutations in hematopoietic stem cells contribute to a prothrombotic state, independent of overt cancer. This review synthesizes current epidemiological data, mechanistic insights, clinical features, diagnostic strategies, management approaches, and recent advances in the field. Emphasis is placed on the practical implications for clinicians, including guideline recommendations and future directions for research and patient care.

Introduction

Clonal hematopoiesis refers to the expansion of blood cell clones harboring acquired somatic mutations, most commonly in genes such as DNMT3A, TET2, and ASXL1. While initially recognized for its role in predisposing individuals to hematologic malignancies, accumulating evidence now implicates CH as an independent risk factor for cardiovascular disease, particularly thrombotic complications. This paradigm shift challenges clinicians to incorporate CH status into cardiovascular risk stratification, even in the absence of cancer. Understanding the mechanisms and clinical implications of CH-associated thrombosis is therefore essential for comprehensive patient management.

Epidemiology / Disease Burden

Population studies indicate that CH becomes increasingly prevalent with age, affecting approximately 10-20% of individuals over 70 years old. While the lifetime risk of progression to hematologic malignancy remains modest (0.5-1% per year), the presence of CH confers a 1.5- to 2-fold increased risk of coronary heart disease, stroke, and venous thromboembolism. Large cohort analyses, such as those from the Framingham Heart Study and UK Biobank, have consistently demonstrated a higher incidence of cardiovascular events in individuals with CHIP mutations, highlighting the substantial disease burden associated with CH in the aging population.

Pathophysiology

The mechanistic link between CH and thrombosis is multifactorial. Mutations in genes like TET2 and DNMT3A lead to altered hematopoietic stem cell function and the preferential expansion of mutated clones. These clones exhibit a pro-inflammatory phenotype, with monocytes and macrophages demonstrating increased production of interleukin-1β and other inflammatory mediators. This chronic inflammatory state promotes endothelial dysfunction, platelet activation, and a hypercoagulable milieu. Animal models have shown that TET2-deficient hematopoietic cells accelerate atherosclerosis and enhance thrombus formation following vascular injury. The interaction between mutant myeloid cells and the vascular endothelium is central to the prothrombotic effects observed in CH.

Risk Factors

Non-modifiable risk factors for CH include advancing age and genetic predisposition. Environmental factors such as smoking, exposure to chemotherapeutic agents, and chronic inflammatory conditions may also promote clonal expansion. The presence of specific mutations (e.g., JAK2 V617F) is associated with a particularly high thrombotic risk, even in the absence of myeloproliferative neoplasms. Co-existing cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia may have additive or synergistic effects with CH in promoting thrombosis.

Clinical Features

Patients with CH are often asymptomatic and may present incidentally with unexplained cytopenias or subtle hematologic abnormalities. However, an increasing body of evidence points to a higher incidence of acute myocardial infarction, ischemic stroke, and venous thromboembolism in this population. Notably, the risk is independent of traditional cardiovascular risk factors and may affect individuals with otherwise low baseline risk. Clinical manifestations are thus heterogeneous and can mimic those of arteriosclerotic or embolic disease, underscoring the necessity for heightened clinical vigilance.

Diagnosis

Diagnosis of CH is primarily molecular, requiring next-generation sequencing (NGS) of peripheral blood to detect somatic mutations with variant allele frequencies (VAF) typically above 2%. Commonly implicated genes include DNMT3A, TET2, ASXL1, and JAK2. Routine screening is not yet recommended for the general population but may be considered in individuals with unexplained thrombotic events or persistent cytopenias. Ancillary laboratory findings, such as mild leukocytosis or anemia, may support the diagnosis but are not specific. Integration of molecular results with clinical context remains crucial for risk stratification.

Treatment & Management

There are currently no established therapies specifically targeting CH in the absence of overt hematologic malignancy. Management focuses on aggressive control of traditional cardiovascular risk factors and consideration of antithrombotic therapy in high-risk individuals. Statins and anti-inflammatory agents may be beneficial given the central role of inflammation in CH-mediated thrombosis. Multidisciplinary collaboration between hematology, cardiology, and primary care is recommended to individualize patient care. Clinical trials evaluating targeted therapies, such as IL-1β inhibitors, are ongoing and may inform future management strategies.

Recent Advances / Emerging Therapies

Recent research has deepened our understanding of the molecular pathways linking CH to thrombosis, with studies demonstrating that anti-inflammatory therapies (e.g., canakinumab) may attenuate cardiovascular risk in individuals with CH. The use of NGS panels for early detection and risk stratification is expanding. Novel agents targeting clonal expansion and inflammatory signaling pathways are under investigation. Additionally, studies are exploring the potential of personalized antithrombotic regimens based on mutation profile and VAF. These advances hold promise for more precise and effective interventions in the near future.

Guideline Recommendations

Current guidelines from major hematology and cardiology societies recognize CH as a non-traditional cardiovascular risk factor but do not yet recommend routine screening or mutation-specific therapy in asymptomatic individuals. Emphasis is placed on standard cardiovascular risk modification and consideration of CH status in patients with unexplained thrombotic events. Ongoing clinical trials and longitudinal studies are expected to inform future guideline updates. Clinicians should remain abreast of emerging evidence and incorporate CH into holistic risk assessment frameworks where appropriate.

Conclusion

Clonal hematopoiesis represents a paradigm shift in our understanding of thrombotic risk, extending its clinical relevance well beyond hematologic malignancies. The interplay between somatic mutations, systemic inflammation, and vascular pathology underscores the need for integrated clinical management and ongoing research. As our knowledge of the molecular and clinical landscape of CH expands, it is imperative for healthcare professionals to recognize and address this emerging risk factor in their practice, optimizing patient outcomes through evidence-based strategies and multidisciplinary collaboration.